Dear Group
Could you share me this article?
J Rheumatol. <https://www.ncbi.nlm.nih.gov/pubmed/12180720#> 2002
Aug;29(8):1623-30.
A randomized, controlled, clinical trial of etoricoxib in the treatment of
rheumatoid arthritis.
Matsumoto AK
<https://www.ncbi.nlm.nih.gov/pubmed/?term=Matsumoto%20AK%5BAuthor%5D&cauthor=true&cauthor_uid=12180720>
1, Melian A
<https://www.ncbi.nlm.nih.gov/pubmed/?term=Melian%20A%5BAuthor%5D&cauthor=true&cauthor_uid=12180720>,
Mandel DR
<https://www.ncbi.nlm.nih.gov/pubmed/?term=Mandel%20DR%5BAuthor%5D&cauthor=true&cauthor_uid=12180720>,
McIlwain HH
<https://www.ncbi.nlm.nih.gov/pubmed/?term=McIlwain%20HH%5BAuthor%5D&cauthor=true&cauthor_uid=12180720>,
Borenstein D
<https://www.ncbi.nlm.nih.gov/pubmed/?term=Borenstein%20D%5BAuthor%5D&cauthor=true&cauthor_uid=12180720>,
Zhao PL
<https://www.ncbi.nlm.nih.gov/pubmed/?term=Zhao%20PL%5BAuthor%5D&cauthor=true&cauthor_uid=12180720>,
Lines CR
<https://www.ncbi.nlm.nih.gov/pubmed/?term=Lines%20CR%5BAuthor%5D&cauthor=true&cauthor_uid=12180720>,
Gertz BJ
<https://www.ncbi.nlm.nih.gov/pubmed/?term=Gertz%20BJ%5BAuthor%5D&cauthor=true&cauthor_uid=12180720>,
Curtis S
<https://www.ncbi.nlm.nih.gov/pubmed/?term=Curtis%20S%5BAuthor%5D&cauthor=true&cauthor_uid=12180720>;
Etoricoxib Rheumatoid Arthritis Study Group
<https://www.ncbi.nlm.nih.gov/pubmed/?term=Etoricoxib%20Rheumatoid%20Arthritis%20Study%20Group%5BCorporate%20Author%5D>
.
Author information <https://www.ncbi.nlm.nih.gov/pubmed/12180720#>
Abstract
OBJECTIVE:
To evaluate the efficacy and tolerability of the highly selective
cyclooxygenase-2 (COX-2) inhibitor etoricoxib for the treatment of
rheumatoid arthritis (RA).
METHODS:
A double blind, randomized, placebo and active comparator controlled, 12
week study conducted at 88 US sites. Eligible patients were chronic
nonsteroidal antiinflammatory drug (NSAID) users with clinical worsening of
RA upon withdrawal of prestudy NSAID. Patients received either placebo,
etoricoxib 90 mg once daily, or naproxen 500 mg twice daily (2:2:1
allocation ratio). Primary efficacy measures: patient and investigator
global assessments of disease activity and direct assessment of arthritis
by counts of tender and swollen joints. Key secondary measures: patient
global assessment of pain, the Stanford Health Assessment Questionnaire,
and the percentage of patients both completing the study and meeting the
ACR20 criteria. Tolerability was assessed by tabulation of adverse events
and routine laboratory evaluations.
RESULTS:
In all, 816 patients were randomized (placebo = 323, etoricoxib = 323,
naproxen = 170), and 448 completed 12 weeks of treatment (placebo = 122,
etoricoxib = 230, naproxen = 96). Compared with patients receiving placebo,
patients receiving etoricoxib and naproxen showed significant improvements
in all efficacy endpoints (p < 0.01). Compared with patients receiving
naproxen, patients receiving etoricoxib demonstrated significant
improvements (p < 0.05) on all primary endpoints and most other endpoints
including ACR20 criteria. The percentage of patients who achieved an ACR20
response and who completed the study was 21%, 53%, and 39% in the placebo,
etoricoxib and naproxen groups, respectively. Etoricoxib and naproxen were
both generally well tolerated.
CONCLUSION:
In this study, etoricoxib 90 mg once daily was more effective than either
placebo or naproxen 500 mg twice daily for treating patients with RA over
12 weeks. Etoricoxib 90 mg was generally well tolerated in patients with RA.
Comment in
- Another selective COX-2 inhibitor: more questions than answers?
<https://www.ncbi.nlm.nih.gov/pubmed/12180711> [J Rheumatol. 2002]
PMID: 12180720
GERARDO GUTIERREZ
MEDICAL LIBRARY
EDUFARM
|
